Results 31 to 40 of about 1,428 (167)

Long-term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study. [PDF]

J Diabetes Investig
ABSTRACT Aims To investigate the long‐term renal effects of tofogliflozin, with the shortest half‐life among sodium–glucose cotransporter 2 inhibitors, in real‐world clinical practice. Materials and methods We retrospectively enrolled patients with type 2 diabetes mellitus treated at three affiliated hospitals between January 2015 and May 2024.
Shinagawa N, Okada H, Hironaka J, Yamamoto S, Yoneda M, Kawai S, Saijyo Y, Katayama T, Nakajima H, Kishi A, Kitagawa N, Nakanishi N, Hamaguchi M, Fukui M.   +13 more
europepmc   +2 more sources

Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice [PDF]

Journal of Diabetes Investigation
Aims/Introduction Sodium–glucose cotransporter 2 (SGLT2) inhibitors effectively and safely reduce fasting and postprandial hyperglycemia while promoting weight loss. However, their unique mechanism of action contributes to concerns regarding their safety.
Yuichiro Yamada, Daisuke Yabe, Kenichiro Shide, Atsushi Suzuki, Yasuo Terauchi, Yasunori Sato, Nobuyuki Shihara, Yutaka Seino   +7 more
doaj   +2 more sources

Correspondence: Effects of short-term tofogliflozin treatment on insulin secretory capacity in type 2 diabetes: Insights and future directions. [PDF]

J Diabetes Investig
Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1440-1441, August 2026.
Bisht G, Indora NK.
europepmc   +2 more sources

Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model [PDF]

Frontiers in Pharmacology, 2014
Renal sodium-dependent glucose co-transporter 2 (SGLT2) is one of the most promising targets for the treatment of type 2 diabetes. Two SGLT2 inhibitors, dapagliflozin and canagliflozin, have already been approved for use in USA and Europe; several ...
Oleg eDemin Jr, Tatiana eYakovleva, Dmitry eKolobkov, Oleg eDemin   +3 more
doaj   +2 more sources

Correction to "Effects of short-term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP-2ELM study". [PDF]

J Diabetes Investig
Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1638-1638, September 2026.
europepmc   +2 more sources

Effect of sodium-glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims-based cohort study. [PDF]

J Diabetes Investig
SGLT2 inhibitor use at discharge was associated with a reduced risk of heart failure readmission in elderly patients with diabetes, with no significant differences among individual agents. ABSTRACT Aims To evaluate the effect of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission ...
Hiura K, Masuda H, Sakunami M, Yamashita M.   +3 more
europepmc   +2 more sources

The sodium‐glucose co‐transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE‐deficient mice with streptozotocin‐induced diabetes

Pharmacology Research & Perspectives, 2022
Epidemiological and animal studies have revealed that sodium‐glucose cotransporter 2 (SGLT2) inhibitors suppress cardiovascular events in subjects with type 2 diabetes and atherosclerosis in animal models of diabetes. However, it still remains unclear if
Masahiko Iwamoto, Tetsuya Kubota, Yoshitaka Sakurai, Nobuhiro Wada, Seiji Shioda, Toshimasa Yamauchi, Takashi Kadowaki, Naoto Kubota   +7 more
doaj   +1 more source

Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients. [PDF]

, 2021
関西医科大学博士（医学）令和3年度Recent studies have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors have a favorable effect on cardiovascular events in diabetic patients.
Sugiura, Tetsuro, Matsumura, Koichiro, Kin, Hiromi, Shibutani, Hiroki, Takahashi, Hiroki, Park, Haengnam, Shiojima, Ichiro, Yamamoto, Yoshihiro, オオタガキ, ムネミツ, Fujii, Kenichi, Otagaki, Munemitsu, 太田垣, 宗光, Matsumoto, Hiroshi   +12 more
core   +1 more source

Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial

Cardiovascular Diabetology, 2021
Background Tofogliflozin, an SGLT2 inhibitor, is associated with favorable metabolic effects, including improved glycemic control and serum lipid profile and decreased body weight, visceral adipose tissue, and blood pressure (BP).
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, On behalf of the UTOPIA study investigators   +26 more
doaj   +1 more source

Tofogliflozin: the road goes ever on [PDF]

Expert Opinion on Pharmacotherapy, 2014
Several drugs are available for the treatment of type 2 diabetes mellitus (T2DM), but few patients achieve and maintain glycaemic control without weight gain and hypoglycaemias. Sodium glucose co-transporter 2 (SGLT-2) inhibitors are an emerging class of drugs with an original mechanism of action involving inhibition of renal glucose reabsorption.
Kalliopi, Pafili, Nikolaos, Papanas
openaire   +2 more sources